Table 2.

Gepants and Ditans studies analyzed.

Drug	Identifier	Disease	Estimated Enrollment	Study Description	Intervention	Phase	Sponsors	Reference
Atogepant	NCT02848326	Migraine with or without aura	834	Safety and tolerability of Atogepant.	10 mg QD	2/3	Allergan	[20]
					30 mg QD
					30 mg BID
					60 mg QD
					60 mg BID
Ubrogepant	NCT02828020	Migraine with or without aura	1672	Efficacy, safety, and tolerability of 2 doses of ubrogepant.	50 mg	3	Allergan	[25]
					100 mg
	NCT02867709	Migraine with or without aura	1686	Efficacy, safety, and tolerability of 2 doses of ubrogepant.	25 mg	3	Allergan	[26]
					50 mg
	NCT02873221	Migraine with or without aura	1254	Evaluate the long-term safety and tolerability of ubrogepant over 1 year.	50 mg	3	Allergan	[27]
					100 mg
	NCT01613248	Migraine	834	Assess the effectiveness, safety and tolerability of a range of doses of MK-1602 versus placebo.	1 mg	2	Allergan	[29]
					10 mg
					25 mg
					50 mg
					100 mg
Zavegepant	NCT03872453	Migraine	2154	Safety and efficacy of three different intranasal dose levels.	10 mg	2/3	Biohaven Pharmaceuticals	[31]
					20 mg
					5 mg
Rimegepant	NCT03235479	Migraine/Acute migraine	1485	Compare the efficacy of BHV-3000 vs. placebo in subjects with acute migraines.	75 mg	3	Biohaven Pharmaceuticals	[33]
	NCT03266588	Migraine with or without aura	3019	Evaluate safety and tolerability of BHV-3000.	75 mg	2/3	Biohaven Pharmaceuticals	[34]
	NCT01430442	Migraine	1026	Evaluate the efficacy of rimegepant compared with placebo in the acute treatment of migraine.	10 mg	2	Biohaven Pharmaceuticals	[35]
					25 mg
					75 mg
					150 mg
					300 mg
					600 mg
	NCT03237845	Migraine Disorders	1499	Compare the efficacy of BHV-3000 vs. placebo in subjects with acute migraines.	75 mg	3	Biohaven Pharmaceuticals	[36]
		Photophobia
		Phonophobia
		Acute Migraine
	NCT03461757	Migraine with or without aura	1811	Compare the efficacy of BHV-3000 vs. placebo in subjects with acute migraines.	75 mg	3	Biohaven Pharmaceuticals	[37]
Lasmiditan	NCT02439320	Acute Migraine	2231	A prospective study in participants with disabling migraine.	100 mg	3	Eli Lilly and Company	[42]
					200 mg		CoLucid Pharmaceuticals
	NCT02605174	Migraine with or without Aura	3005	A prospective study in participants with disabling migraine.	50 mg	3	Eli Lilly and Company	[43]
					100 mg		CoLucid Pharmaceuticals
					200 mg
	NCT02565186	Migraine Disorders	2171	Safety Study of Lasmiditan in the acute treatment of migraine.	100 mg	3	Eli Lilly and Company	[44]
					200 mg		CoLucid Pharmaceuticals
	NCT00883051	Migraine disorders	512	Efficacy and safety of a range of oral doses of	50 mg	2	Eli Lilly and Company	[46]
				COL-144 in treating migraine headache.	100 mg		CoLucid Pharmaceuticals
					200 mg
					400 mg